Stroke, depression, and self-harm in later life.

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Trials

Background:

• Poststroke depression affects approximately one in three survivors within 12 months.
• Depressive symptoms can persist or recur in 30% of individuals over 12 months.
• Stroke survivors report suicidal ideation more frequently than the general population.

Purpose of the Study:

• To review randomized placebo-controlled trials on selective serotonin reuptake inhibitors (SSRIs) for poststroke depression and suicidal ideation.
• To evaluate the clinical efficacy and safety of SSRIs in stroke survivors.

Main Methods:

• Systematic review of recent randomized placebo-controlled trials.
• Analysis of data on depression prevalence and suicidal ideation.
• Assessment of adverse events associated with SSRI treatment.

Main Results:

• Daily fluoxetine (20 mg for 6 months) did not alter depression prevalence or suicidal ideation in stroke survivors.
• Antidepressant treatment led to higher rates of discontinuation, seizures, and bone fractures compared to placebo.
• No significant reduction in depressive symptoms or suicidal thoughts was observed with SSRI treatment.

Conclusions:

• Current evidence questions the effectiveness and safety of SSRIs for managing and preventing poststroke depression.
• Further research is needed to clarify SSRI efficacy in severe stroke cases or major depressive episodes.